Transcriptional Characterization of Compounds: Lessons Learned from the Public LINCS Data

Assay and Drug Development Technologies

Volumn 14, Issue 4, 2016, Pages 252-260

  De Wolf, Hans ^a   De Bondt, An ^a   Turner, Heather ^b   Göhlmann, Hinrich W H ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b Open Analytics   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CELL LINE; DNA TRANSCRIPTION; EXPERIMENTAL DESIGN; HUMAN; HUMAN CELL; A-549 CELL LINE; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE LIBRARY; GENETIC DATABASE; GENETIC TRANSCRIPTION; GENETICS; HEP-G2 CELL LINE; HT-29 CELL LINE; MCF-7 CELL LINE; PROCEDURES;

ANTINEOPLASTIC AGENT; TRANSCRIPTOME;

A549 CELLS; ANTINEOPLASTIC AGENTS; DATABASES, GENETIC; GENE EXPRESSION PROFILING; GENE LIBRARY; HEP G2 CELLS; HT29 CELLS; HUMANS; MCF-7 CELLS; TRANSCRIPTION, GENETIC; TRANSCRIPTOME;

EID: 84969850505     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2016.715     Document Type: Article

References (23)

1. Drews J: Drug discovery: A historical perspective. Science 2000;287:1960-1964.
2. Iorio F, Rittman T, Ge H, et al.: Transcriptional data: A new gateway to drug repositioning? Drug Discov Today 2013;18: 350-357.
3. Lamb J, Crawford ED, Peck D, et al.: The connectivity map: Using geneexpression signatures to connect small molecules, genes and diseases. Science 2006;313:1929-1935.
4. Lamb J: The connectivity map: A new tool for biomedical research. Nat Rev Cancer 2007;7:54-60.
5. D'Arcy P, Brnjic S, Olofsson MH, et al.: Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med 2011;17:1636-1640.
6. Finley SD, Chu L-H, Popel AS: Computational systems biology approaches to anti-angiogenic cancer therapeutics. Drug Discov Today 2015;20:187-197.
7. Verbist B, Verheyen GE, Vervoort L, et al.: Integrating high-dimensional transcriptomics and image analysis tools into early safety screening: A proofof-concept for a new early drug development strategy. Chem Res Toxicol 2015;28:1914-1925.
8. Liu C, Su J, Yang F, Wei K, Ma J, Zhou X: Compound signature detection on LINCS L1000 big data. Mol Biosyst 2015;11:714-722.
9. Peck D, Crawford ED, Ross KN, Stegmaier K, Golub TR, Lamb J: A method for high-throughput gene expression signature analysis. Genome Biol 2006;7:R61.
10. Ritchie ME, Phipson B, Wu D, et al.: Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015;43:7:e47.
11. Smyth GK: Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3.
12. McCarthy DJ, Smyth GK: Testing significance relative to a fold-change threshold is a TREAT. Bioinformatics 2004;25:765-771.
13. Benjamini Y, Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. JRSS B 1995;57:289-300.
14. Smyth GK, Michaud J, Scott H: The use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 2005;21:2067-2075.
15. Within PCA and Between PCA. Available at: https://pbil.univ-lyon1.fr/R/pdf/ course4.pdf (Last accessed April 17, 2016).
16. Lacevic B, Amaldi E: Ectropy of diversity measures for populations in Euclidean space. Inf Sci 2011;181:2316-2339.
17. Wawer MJ, Li K, Gustafsdottir SM, et al.: Toward performance diverse smallmolecule libraries for cell-based phenotypic screening using multiplexed highdimensional profiling. Proc Natl Acad Sci 2014;111:10911-10916.
18. R: A language and environment for statistical computing. Available at: www.R-project.org (Last accessed July 10, 2014).
19. Peng T, Golub RT, Sabatini MD: The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol 2002;22:5575-5584.
20. Fournier MV, Martin KJ, Kenny PA, et al.: Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. Cancer Res 2006;66:7095-7102.
21. Ciuffreda L, Del Bufalo D, Desideri M, et al.: Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia 2009;11:720-731.
22. Iorio F, Bosotti R, Scacheri E, et al.: Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A 2010;107:14621-16626.
23. Nigsch F, Hutz J, Cornett B, et al.: Determination of minimal transcriptional signatures of compounds for target prediction. EURASIP J Bioinform Syst Biol 2012;2012:2.